Bruker & KIESTRA Lab Automation Announce Alliance in Microbial Identification by MALDI Biotyper Molecular Fingerprinting & Mi...
April 09 2010 - 12:00AM
Business Wire
Prior to the 20th Annual Meeting of the European Society of
Clinical Microbiology and Infectious Diseases on April 10-13, 2010
in Vienna, Bruker Daltonics and KIESTRA Lab Automation announce an
expanded partnership covering co-marketing and cross-selling of
their respective technologies for microbiology routine
laboratories, as well as a joint research and development program
for interfacing their technologies.
In recent years, Bruker and KIESTRA Lab Automation have worked
with a number of customers applying both technologies in their
laboratories. Together with the Academical Medical Center
(Amsterdam), the Jeroen Bosch Hospital (Den Bosch), Leiden
University Medical Center (Leiden) and Streeklab Haarlem (Haarlem),
both companies applied for the prestigious European Research
Initiative EUREKA (www.eureka.be). Typically, EUREKA R&D is
lead by industry and is focused on significant new customer
requirements. In March 2010, the participating project partners
ranked at third position of the EUREKA tender for their joint 24/7
Bacteriology Identification & Sensitivity System (BISS)
project. In addition to integration of both technologies, a goal of
the BISS project is to enable unattended 24/7 operation for
bacterial identification.
Mr. Jetze Botma, Chief Executive Officer at KIESTRA Lab
Automation, stated: “It is remarkable to see how relatively new
players in the microbiology market have changed the competitive
landscape in the last couple of years. The trends of consolidation
of laboratories and of centralizing microbiology laboratory
services will further increase the demand for professional
automation solutions. In addition, an early identification by the
MALDI Biotyper in many cases can already initiate a germ-specific
therapy, which leads to a significant increase in laboratory and
hospital efficacy. The effective combination of both technologies
will help to ease the burden on the healthcare system.”
Dr. Wolfgang Pusch, Vice President for Clinical Research
Solutions & IVD at Bruker Daltonics, added: “This strategic
partnership with KIESTRA Lab Automation is an excellent match for
Bruker. We are two leading suppliers offering innovative
technologies for the microbiology market, in laboratory automation
and in molecular microbial ID. Each of our technologies alone has
been quite successful already, and in combination they could change
the way microbiology is performed in many routine labs. KIESTRA´s
technology brings the same level of automation into the
microbiology lab that was introduced in clinical chemistry 15 years
ago. Moreover, the MALDI Biotyper reduces the identification
turnaround time for patient samples significantly. Both
technologies integrated together will help microbiology
laboratories to perform their important tasks faster and better,
despite a predicted shortage in experienced laboratory staff.”
About the Bruker MALDI Biotyper
Bruker’s proprietary MALDI Biotyper solution enables molecular
identification, taxonomical classification or dereplication of
microorganisms like bacteria, yeasts and fungi. Classification and
identification of microorganisms is achieved reliably and quickly
using proteomic fingerprinting by high-throughput MALDI-TOF mass
spectrometry. Applications include clinical routine microbial
identification, environmental and pharmaceutical analysis,
taxonomical research, food and consumer product processing and
quality control, as well as marine microbiology. Bruker’s robust
MALDI Biotyper method requires minimal sample preparation efforts
and offers low consumables cost per sample. The MALDI Biotyper is
available in a research-use-only version, as well as in an IVD-CE
version according to EU directive EC/98/79 in certain European
countries. For more information, please visit
www.maldibiotyper.com.
For more information about Bruker Daltonics and Bruker
Corporation (NASDAQ: BRKR), please visit www.bdal.com and
www.bruker.com/.
About Kiestra’s MalditofA for Fully Automatic Colony
Picking
Bruker’s MALDI-TOF technology is a true revolution within
medical bacteriology. KIESTRA launches a full automatic colony
picker, called MalditofA. The automatic transfer of a colony to the
target plate by the MalditofA guarantees that possible manual
mismatches are prevented. In order to enhance susceptibility
testing, the MalditofA also automatically creates the suspension
fluid at. e.g. 0.5 McFarland. The MalditofA makes sure laboratories
can take advantage to reduce id-card usage while labor costs are
reduced dramatically.
For more information about KIESTRA Lab Automation, please visit
www.kiestra.nl.
CAUTIONARY STATEMENT OF BRUKER
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to adverse
changes in conditions in the global economy and volatility in the
capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product
development and market acceptance of our products, the cost and
pricing of our products, manufacturing, competition, dependence on
collaborative partners and key suppliers, capital spending and
government funding policies, changes in governmental regulations,
intellectual property rights, litigation, and exposure to foreign
currency fluctuations. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2009, our most recent quarterly reports on Form
10-Q and our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements other than as
required by law.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6243451&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024